Sugi Predict

Sugi Predict / Compounds / SCHEMBL995814

SCHEMBL995814

SCHEMBL995814

CC(=O)N1CCC2(CC1)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 5/20 0.47
▸ GPR183 P32249 1/20 0.47
▸ SCD5 Q86SK9 1/20 0.46
▸ CYP11B2 P19099 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ USP2 O75604 3/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ CYP2D6 P10635 1/20 0.44
▸ CYP4F2 P78329 1/20 0.44
▸ CYP4A11 Q02928 1/20 0.44
▸ CYP2C9 P11712 1/20 0.43
▸ HDAC2 Q92769 2/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ TSHR P16473 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18711285 0.93 CYP4F2 (0.47) ACACBGPR183SCD5CYP11B2ALDH1A1
SCHEMBL4271629 0.93 CYP11B2 (0.51) ACACBGPR183SCD5CYP11B2ALDH1A1
SCHEMBL20669220 0.93 SCD5 (0.49) ACACBGPR183SCD5CYP11B2ALDH1A1
SCHEMBL18711499 0.93 USP2 (0.49) ACACBGPR183SCD5CYP11B2ALDH1A1
SCHEMBL18711501 0.90 CYP11B2 (0.48) ACACBGPR183SCD5CYP11B2ALDH1A1
SCHEMBL742156 0.90 USP2 (0.51) ALDH1A1USP2SMN1; SMN2CYP2D6CYP4F2
SCHEMBL3748431 0.88 CYP2D6 (0.50) ACACBSCD5CYP11B2ALDH1A1CYP2C19
SCHEMBL31173719 0.87 SCD5 (0.49) ACACBGPR183SCD5CYP11B2CYP2C19
SCHEMBL2593841 0.86 SMN1; SMN2 (0.46) ACACBGPR183CYP11B2USP2SMN1; SMN2
SCHEMBL16573803 0.86 USP2 (0.48) ACACBGPR183SCD5CYP11B2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 — — US disclosed
WO-2025215110-A1 NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS LES LABORATOIRES SERVIER (FR) 2025-10-16 — — WO disclosed
WO-2024211834-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 — — EP disclosed
CN-110637025-B Peptide amide compound, preparation method and medical application thereof 四川海思科制药有限公司 2023-07-18 — — CN disclosed
EP-3656782-B1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) 2021-12-22 — — EP disclosed
EP-3656782-B1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) 2021-12-22 — — EP disclosed
US-11014964-B2 Peptide amide compound and preparation method and medical use thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2021-05-25 — — US disclosed
US-11014964-B2 Peptide amide compound and preparation method and medical use thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2021-05-25 — — US disclosed
EP-3656782-A1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2020-05-27 — — EP disclosed
CN-110637025-A Peptide amide compound, preparation method and medical application thereof 四川海思科制药有限公司 2019-12-31 — — CN disclosed
WO-2019015644-A1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF 四川海思科制药有限公司 2019-01-24 — — WO disclosed
WO-2019015644-A1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF 四川海思科制药有限公司 2019-01-24 — — WO disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 — — US disclosed
EP-2205610-B1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS HOFFMANN LA ROCHE (CH) 2013-11-20 — — EP disclosed
US-8293735-B2 Thienopyrimidine derivatives as P13K inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2012-10-23 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
EP-2205610-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN ACACB 435/4885GPR183 2474/4885SCD5 3572/4885
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS PIK3CA, PIK3CD, PIK3CB ACACB 3511/4885GPR183 2755/4885SCD5 3878/4885
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS SPR, QDPR, SRR ACACB 1555/4885GPR183 1543/4885SCD5 291/4885
US-11014964-B2 Peptide amide compound and preparation method and medical use thereof VIP, NPPA, GRPR ACACB 2840/4885GPR183 883/4885SCD5 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.